Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idasanutlin with cytarabine and daunorubicin in newly diagnosed AML, with idasanutlin maintenance in first remission
2018-002964-25Phase 2Terminated
- Sponsor
- Roche
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of idasanutlin in acute myeloid leukemia (AML) (2 arms), sponsored by Roche. Primary endpoint: Incidence of dose-limiting toxicities. Started Apr 2019; status: terminated.
02
Drugs
idasanutlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-002964-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002964-25.